InMed Pharmaceuticals Inc. (INM) CEO Eric Adams on Q4 2021 Results - Earnings Call Transcript

InMed Pharmaceuticals Inc. (NASDAQ:INM) Q4 2021 Earnings Conference Call September 24, 2021 11:00 AM ET

Company Participants

Colin Clancy - Senior Director of Investor Relations
Eric Adams - President and Chief Executive Officer
Bruce Colwill - Chief Financial Officer
Eric Hsu - Senior Vice President, Preclinical Research and Development
Alexandra Mancini - Senior Vice President, Clinical and Regulatory Affairs
Michael Woudenberg - Vice President, Chemistry, Manufacturing and Control

Conference Call Participants

Scott Henry - ROTH capital Partners
Max Jacobs - Edison Investment Research

Operator

Thank you for standing by and welcome to the InMed Pharmaceuticals Inc. Fourth Quarter Fiscal 2021 Financial Results and Business Update. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions]. As a reminder today's program maybe recorded.

I would now like to introduce your host for today's program, Bruce Colwill, Chief Financial Officer. Please go ahead sir.

Colin Clancy

Thank you, Jonathan, and good day, ladies and gentlemen. My name is Colin Clancy, InMed's Senior Director of Investor Relations. Welcome to InMed’s fourth quarter and full year fiscal 2021 financial results and business update conference call. Please note our speakers are joining us today from remote locations, so we appreciate your patience if we encounter any unexpected technical challenges.

Before we begin, we would like to go over our disclosure statements, followed by a review of our recent announcement to acquire BayMedica together with a progress update on our cannabinoid manufacturing and therapeutic development programs, which will be led by our President and CEO, Eric Adams. Mr. Bruce Colwill, our Chief Financial Officer will then review the financial results of operations. Following that, we will be available for a question-and-answer session.

Also joining us today to address your questions will be Eric Hsu, Senior